In November 2022 results from the third round of tenders were announced. This time HivNorway is pleased with the outcome. Two significant positive outcomes from this round of tenders is that the medications on the list are all combination tablets, or single tablets. Secondly, there is equal recommendations from the national guidelines for hiv treatment and the outcome of the medication subject to tenders. This time it is also more clearly spesified that any medical reasons why a person should be prescribed medication different from what is on the list, can be justified in the patients records. It is therefore important that you have a close and open dialogue with your medical doctor so you can receive the most appropriate medication taking into consideration guidelines, cost, overall health and wellbeing.

These are the combinations that won the tender in 2022:

1. Delstrigo (doravirin/lamivudine/tenofovir disproksil)
2. Dovato (dolutegravir/lamivudine)
3. Triumeq (dolutegravir/abacavir/lamivudine)
4. Biktarvy (biktegravir/emtricitabine/TAF)

Genvoya, a medication commonly used, shall be changed to other medications as it is no longer among the recommended tablets.

If you have any other questions or need assistance, please do not hesitate to contact us. You can reach us by phone 21314580, via Messenger, on our Facebook page (HivNorge) or via email.